Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

3 Passive Income Stocks To Scoop Up Now

These three stocks have earned the title of Dividend Kings by consistently increasing dividends for at least 50 years.

Barchart

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Top Dividend Kings to Earn Passive Income

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

Barchart

AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for AbbVie shows improving technical performance.

Investors Business Daily

Drug Maker AbbVie Stock Sees RS Rating Jump To 81

AbbVie shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.

AbbVie raised its long-term guidance for Skyrizi and Rinvoq, two key immunology drugs, on Friday. AbbVie stock inched higher.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

StockNews.com

AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

A new test could save arthritis patients time, money and pain. But will it be used?

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

WEKU

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

Stock market today: Asian shares are mostly higher ahead of a key US jobs report

Asian shares are mostly higher ahead of a U.S. jobs report after Wall Street rose Thursday to snap its first three-day losing streak since Halloween

The Independent UK

What it really takes to be a great place to work

There’s no one-size-fits-all model, but it can be done at virtually any organization.

Fortune

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Broader Market Settles Higher on Improved Soft-Landing Prospects

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. Stocks on Thursday settled mixed, with the Dow Jones...

Barchart

Stocks Mixed as Higher Bond Yields Weigh on Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.84%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.77%. Stocks this morning are mixed, with the Dow Jones...

Investors Business Daily

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

Barchart

3 Defensive Dividend Stocks to Protect Your Portfolio

Dividend-paying stocks are having a tough year, but there are still some top-rated income picks worth buying at current levels. Here's a look at three dividend stocks that can actually help defend your portfolio from market volatility.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

Investors Business Daily

AbbVie Stock Dives As Cosmetic Sales Mar Its Third-Quarter Beat And Guidance Boost

AbbVie posted a nearly perfect third-quarter beat Friday, but AbbVie stock skidded on light aesthetics sales and as Humira sales fell.

Investors Business Daily

Drugmaker AbbVie Stock Sees Improved Relative Price Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

AbbVie Stock Moves Higher With Rising Relative Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

AbbVie Stock Shows Rising Relative Strength Rating

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke

Revance is reversing course to stay competitive with AbbVie's aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.

StockNews.com

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.